###begin article-title 0
###xml 18 23 <span type="species:ncbi:9606">human</span>
Regulation of the human AP-endonuclease (APE1/Ref-1) expression by the tumor suppressor p53 in response to DNA damage
###end article-title 0
###begin p 1
###xml 0 16 0 16 <!--CREATIVE COMMONS-->
CREATIVE COMMONSThis is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin p 2
###xml 615 620 615 620 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(+/+)</sup>
###xml 4 9 <span type="species:ncbi:9606">human</span>
###xml 576 581 <span type="species:ncbi:9606">human</span>
The human AP-endonuclease (APE1/Ref-1), an essential multifunctional protein, plays a central role in the repair of oxidative base damage via the DNA base excision repair (BER) pathway. The mammalian AP-endonuclease (APE1) overexpression is often observed in tumor cells, and confers resistance to various anticancer drugs; its downregulation sensitizes tumor cells to those agents via induction of apoptosis. Here we show that wild type (WT) but not mutant p53 negatively regulates APE1 expression. Time-dependent decrease was observed in APE1 mRNA and protein levels in the human colorectal cancer line HCT116 p53(+/+), but not in the isogenic p53 null mutant after treatment with camptothecin, a DNA topoisomerase I inhibitor. Furthermore, ectopic expression of WTp53 in the p53 null cells significantly reduced both endogenous APE1 and APE1 promoter-dependent luciferase expression in a dose-dependent fashion. Chromatin immunoprecipitation assays revealed that endogenous p53 is bound to the APE1 promoter region that includes a Sp1 site. We show here that WTp53 interferes with Sp1 binding to the APE1 promoter, which provides a mechanism for the downregulation of APE1. Taken together, our results demonstrate that WTp53 is a negative regulator of APE1 expression, so that repression of APE1 by p53 could provide an additional pathway for p53-dependent induction of apoptosis in response to DNA damage.
###end p 2
###begin title 3
INTRODUCTION
###end title 3
###begin p 4
###xml 339 342 339 342 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1 B2 B3">1&#8211;3</xref>
###xml 572 573 569 570 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 669 677 666 674 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 696 697 693 694 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 843 846 840 843 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6 B7 B8">6&#8211;8</xref>
###xml 886 891 883 888 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trans</italic>
###xml 931 933 928 930 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 969 971 966 968 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2+</sup>
###xml 1043 1047 1040 1044 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B9 B10 B11">9&#8211;11</xref>
###xml 1000 1005 <span type="species:ncbi:9606">human</span>
The mammalian AP-endonuclease (APE1) is a ubiquitous and remarkably multifunctional protein. It plays a central role in the base excision repair (BER) pathway for damaged bases induced by reactive oxygen species and alkylating agents, and for abasic (AP) sites generated after excision of oxidized and alkylated bases by DNA glycosylases (1-3). As an endonuclease, APE1 cleaves the AP site to generate 3'-OH and 5'-deoxyribose phosphate termini, and the 3'-OH terminus is utilized by a DNA polymerase, usually DNA polymerase beta, for repair synthesis in mammalian cells (4). APE1 was independently identified as a reductive activator of the c-Jun transcription factor in vitro, and named Ref-1 (5). Subsequently, several other transcription factors (including p53, hypoxia-inducible factor and NF-kB) were also found to be activated by APE1 (6-8). In addition, APE1 directly acts as a trans-acting factor by binding to negative Ca2+ response elements (nCaRE) during Ca2+-dependent repression of the human parathyroid hormone and renin genes (9-11).
###end p 4
###begin p 5
###xml 85 92 85 92 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 263 268 263 268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12 B13 B14">12&#8211;14</xref>
###xml 405 407 405 407 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 486 488 486 488 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 683 688 683 688 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17 B18 B19 B20">17&#8211;20</xref>
###xml 797 802 797 802 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21 B22 B23">21&#8211;23</xref>
###xml 908 910 908 910 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 911 913 911 913 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 914 916 914 916 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
###xml 1096 1101 1096 1101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26 B27 B28 B29">26&#8211;29</xref>
###xml 1316 1318 1316 1318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B29">29</xref>
###xml 1477 1479 1477 1479 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B29">29</xref>
###xml 1167 1172 <span type="species:ncbi:10090">mouse</span>
###xml 1304 1309 <span type="species:ncbi:9606">human</span>
Given its multiple functions, it is not surprising that APE1 expression is regulated in vivo in a complex manner. We were one of the first to show the activation of APE1 gene by oxidative stress; several other laboratories subsequently confirmed our observation (12-14). Moreover, based on the identification of the nCaREs in the APE1 promoter itself, we suggested that APE1 regulates its own expression (15). While cell cycle-dependent expression of APE1 was observed in NIH3T3 cells (16), the basal expression of APE1 is variable. The increased APE1 level is often observed in tumor cells including prostate, osteosarcomas, lung and cervical carcinomas compared to normal tissues (17-20). In other types of cancer, subcellular localization of APE1 is altered relative to that in normal tissues (21-23). Tumor cells often overexpress APE1 and are resistant to chemotherapeutic drugs and ionizing radiation (19,24,25). In contrast, siRNA-mediated downregulation of APE1 induced apoptosis of many tumor cell types and enhanced cell sensitization to ionizing radiation and chemotherapeutic agents (26-29). We recently showed that APE1 inactivation-induced apoptosis in mouse embryo fibroblasts (MEF) conditionally nullizygous for endogenous APE1, an effect that could be prevented by ectopic expression of human APE1 (29). Using a complementation assay, we also showed that both the repair and transcription regulatory functions of APE1 are required to prevent apoptosis of MEF (29). Thus, elucidating the molecular mechanisms controlling APE1 expression has profound implications for cancer therapy from both basic and clinical perspectives.
###end p 5
###begin p 6
###xml 221 223 221 223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B30">30</xref>
###xml 224 226 224 226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B31">31</xref>
###xml 408 410 408 410 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B32">32</xref>
###xml 411 413 411 413 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B33">33</xref>
###xml 672 674 672 674 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B34">34</xref>
###xml 883 888 879 884 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B35 B36 B37">35&#8211;37</xref>
###xml 1043 1048 1039 1044 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B38 B39 B40">38&#8211;40</xref>
###xml 1149 1157 1145 1153 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">survivin</italic>
###xml 1159 1171 1155 1167 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bcl-2, IGF1R</italic>
###xml 1193 1194 1189 1190 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 1231 1235 1227 1231 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MGMT</italic>
###xml 1294 1299 1290 1295 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B41 B42 B43 B44 B45 B46">41&#8211;46</xref>
###xml 278 283 <span type="species:ncbi:9606">human</span>
###xml 304 309 <span type="species:ncbi:9606">human</span>
The tumor suppressor gene p53, dubbed 'the guardian of the genome', encodes a sequence-specific transcription factor that activates a variety of cellular genes in response to DNA damage, hypoxia and other stress signals (30,31). p53 is one of the most commonly mutated genes in human cancers; 50% of all human cancers lack the wild type (WT) p53 gene allele, and these tumors respond poorly to chemotherapy (32,33). In response to DNA damage or other cellular stresses, p53 is activated and induces cell cycle arrest or apoptosis, depending on the severity of the damage and the context of the cell cycle, and thus helps to maintain genomic stability and prevents cancer (34). Once activated, p53 has the ability to arrest cell cycle by transactivation of Waf-1/p21, 14-3-3delta etc., or induce cells to undergo apoptosis by both transcription-dependent and -independent mechanisms (35-37). p53 activates many downstream target genes involved in the mitochondrial signaling pathway during apoptosis including BAX, PUMA and the death receptor (38-40). In addition, p53 has been shown to downregulate many genes, including cell survival genes such as survivin, bcl-2, IGF1R and DNA repair gene O6-methylguanine-DNA-methyltranferase (MGMT) with the net result of facilitating apoptosis induction (41-46).
###end p 6
###begin p 7
###xml 141 143 141 143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 144 146 144 146 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B47">47</xref>
###xml 780 785 780 785 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(+/+)</sup>
###xml 1122 1129 1122 1129 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 421 426 <span type="species:ncbi:9606">human</span>
###xml 786 791 <span type="species:ncbi:9606">human</span>
Potential link between APE1 expression and p53 status in various tumors and their resistance to chemotherapeutic drugs have been documented (24,47). Despite several studies showing the involvement of APE1 and p53 in drug resistance induction in tumor cells, the question of whether p53 regulates APE1 expression after genotoxic stress has not been addressed. Elucidating the direct role of p53 on APE1 gene expression in human cells should be of major clinical significance, and a clear understanding of the mechanisms by which p53 controls APE1 expression could help in effective use of chemotherapeutic agents in the treatment of tumors expressing WT or mutant p53. In this study, we show that activation of p53 after genotoxic stress downregulates APE1 expression in HCT116 p53(+/+) human colon carcinoma cells, but not in the p53 null mutants derived there from. Transgenic expression of WTp53 in p53 null cells downregulate both endogenous APE1 level and expression of a reporter whose activity is dependent on APE1 promoter activity. We also present evidence that p53 is associated with the endogenous APE1 promoter in vivo, and that interference of specificity protein (Sp1) binding to the APE1 promoter by WTp53 and subsequent recruitment of histone deacetylase (HDAC) to the promoter could explain downregulation of APE1 by WTp53.
###end p 7
###begin title 8
MATERIALS AND METHODS
###end title 8
###begin title 9
Cell culture and treatment
###end title 9
###begin p 10
###xml 53 58 53 58 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(+/+)</sup>
###xml 93 98 93 98 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(&#8722;/&#8722;)</sup>
###xml 421 422 417 418 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 4 9 <span type="species:ncbi:9606">human</span>
###xml 280 286 <span type="species:ncbi:9913">bovine</span>
The human colorectal adenocarcinoma lines, HCT116 p53(+/+) with WTp53 and p53 null HCT116 p53(-/-) (a gift from Dr B. Vogelstein, Johns Hopkins University School of Medicine) were grown in McCoy's 5A (Gibco Life Technologies, Carlsbad, CA, USA) medium supplemented with 10% fetal bovine serum (Sigma-Aldrich, St Louis, MO, USA), 100 U/ml penicillin and 100 microg/ml streptomycin (Gibco BRL, Carlsbad, CA, USA) in a 5% C02 incubator at 37degreesC. Cells were treated with 200 nM camptothecin (CPT) (Sigma, St Louis, MO, USA) and/or 30 microM pifithrin-alpha (PFT-alpha) (Sigma, St Louis, MO, USA).
###end p 10
###begin title 11
Plasmids and luciferase assays
###end title 11
###begin p 12
###xml 150 152 150 152 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 371 376 371 376 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(&#8722;/&#8722;)</sup>
Generation of APE1 promoter-reporter plasmids containing DNA fragments (-4800/+65) and (-1800/+65) of the 5' regulatory region was described earlier (15). Other reporter plasmids with various lengths of the APE1 5' regulatory region were generated by PCR and cloned into the luciferase reporter vector pGL3 (Promega, Madison WI, USA) using standard procedures. HCT116 p53(-/-) cells were cotransfected with 500 ng of the APE1-reporter plasmids and expression plasmids for WT or mutant [Val143Ala (V143A) and L22G, T23S] p53 or equivalent amounts of empty vector using LipofectAMINE 2000 (Invitrogen, Life Technologies, Carlsbad, CA, USA), according to the manufacturer's instructions. At 48 h after the transfections, cells were lysed with the reporter lysis buffer (Promega), and the luciferase activity in the cell lysates was measured in a luminometer (AutoLumant LB593, Berthold, Oak Ridge, TN, USA) by the luciferase assay kit (Promega, Madison, WI, USA) according to the manufacturer's protocol. The luciferase activity was normalized to the amount of protein in the lysate.
###end p 12
###begin title 13
Preparation of total cell extract and western blot analysis
###end title 13
###begin p 14
###xml 185 187 185 187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B48">48</xref>
###xml 390 395 <span type="species:ncbi:10090">mouse</span>
###xml 486 492 <span type="species:ncbi:9986">rabbit</span>
###xml 535 541 <span type="species:ncbi:9986">rabbit</span>
HCT116 cells were lysed in a lysis buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% TritonX-100, and protease inhibitor cocktail (Roche, Nutley NJ, USA) as described earlier (48). Whole-cell extracts (25 microg) were subjected to 12.5% SDS-PAGE and transferred to a nitrocellulose membrane (Trans-Blot 0.2 microm, Bio-Rad, Hercules, CA, USA). Western immunoblotting analyses with mouse monoclonal antip53 antibody (sc-DO-1, dilution 1:200, Santa Cruz Biotechnology, CA, USA), rabbit polyclonal antiAPE1 (dilution 1:2000), or rabbit monoclonal antibeta-actin antibody (Sigma, 1:1000 dilution) were carried out using enhanced chemiluminescence assay (ECL kit, Amersham, London, UK).
###end p 14
###begin title 15
RNA isolation and RT-PCR analysis
###end title 15
###begin p 16
Total RNA was extracted using Rneasy Mini kit (QIAGEN) according to the manufacturer's protocol. For quantitative, real-time RT-PCR, one step RT-PCR was performed with 100 ng of cellular RNA for both the target gene and an endogenous control in singleplex tubes using TaqMan one-step RT-PCR master mixture reagent kit (P/N 4309196). TaqMan MGB probes (FAMTM dye-labeled) for APEX1 gene and 18s rRNA (VICTM-dye labeled probe) TaqMan(R) assay reagent (P/N 4319413E) for endogenous control (assay-on-DemandTM (P/N 4331182) were used. The cycling parameters in an ABI 7000 (Applied Biosystem, Foster City, CA, USA) thermal cycler were as follows: reverse transcription at 48degreesC for 30 min. AmpliTaq activation 95degreesC for 10 min, denaturation 95degreesC for 15s, and annealing/extension 60degreesC for 1 min. The amount of target was calculated after normalization to the 18s RNA as an endogenous control.
###end p 16
###begin title 17
Chromatin immunoprecipitation (ChIP) assay
###end title 17
###begin p 18
###xml 10 15 10 15 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(+/+)</sup>
###xml 30 35 30 35 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(&#8722;/&#8722;)</sup>
###xml 979 980 973 974 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sub>
HCT116 p53(+/+) and HCT116 p53(-/-) cells were treated with CPT at final concentration of 200 nM for 6 h unless otherwise indicated. Cells were washed twice with ice-cold PBS, fixed with 1% formaldehyde for 10 min at RT, washed twice with cold PBS, and harvested in cell scraping solution (1X PBS and 0.5 mM PMSF). Pellets were collected by centrifugation at 1200 rpm for 10 min at 4degreesC and resuspended in ice-cold lysis buffer (Active Motif, ChIP-IT, Carlsbad, CA, USA, supplemented with 0.5 mM PMSF and 0.5 mM protease inhibitor cocktail), and then incubated on ice for 30 min. The DNA fragments were digested with mung bean nuclease to an average size of 200-500 bp, as empirically estimated by agarose gel electrophoresis of the digest. Immunoprecipitations were performed with antip53 (DO-1), IgG (as a negative control) and antiSp1 (as a positive control) antibodies. After sequential washing, DNA-protein complexes were eluted with elution buffer (1% SDS, 0.1 M NaHCO3, 0.01 mg/ml herring sperm DNA). The crosslinks were reversed by heating at 65degreesC overnight, and treatment with proteinase K (0.17 microg/microl) for 1 h, and the DNA then isolated using a column (Active Motif, ChIP-IT) according to the manufacturer's guidelines. Recovered DNA was suspended in 50 microl of TE. PCR amplification of DNA was carried out with diluted aliquots using appropriate primers to generate PCR products spanning +24 to -368 bp and -118 to -253 bp of the APE1 promoter region. The PCR products were separated by 1.5% agarose electrophoresis in Tris-borate-EDTA buffer and stained with ethidium bromide.
###end p 18
###begin title 19
Electrophoretic mobility shift assay (EMSA)
###end title 19
###begin p 20
###xml 77 79 77 79 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B38">38</xref>
###xml 113 115 113 115 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">32</sup>
###xml 494 499 493 498 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(&#8722;/&#8722;)</sup>
###xml 599 600 592 593 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 307 312 <span type="species:ncbi:9606">human</span>
Electrophoretic mobility shift analyses were performed as described earlier (38) with some modifications. The 5' 32P-labeled oligo 5'-AGAGAGGGAGGCGAGGCTAAGCGTCTCCGTCACGT-3' (potential p53-binding site on APE1 promoter) and 5'-TTG AAC ATG TCC CAA CAT GTT GA-3' containing the p53 consensus sequence from the human p21 promoter were annealed with appropriate complementary stands to generate duplex oligos. The DNA (50 fmol) was then incubated with p53 or nuclear extracts (5 mug) from HCT116 p53(-/-) cells for 20 min at 25degreesC in a buffer containing 40 mM HEPES-KOH, pH 7.5, 50 mM KCl, 1 mM MgCl2, 0.5 mM EDTA, 0.5 mM DTT, 10% glycerol, 1 mug of poly dI-dC (Sigma). After electrophoresis in non-denaturing 5% polyacrylamide gels in Tris-borate buffer at 4degreesC, the gels were dried and exposed to PhosphorImager (Molecular Dynamics, Piscataway, NJ, USA) and analyzed using IMAGEQUANT software.
###end p 20
###begin title 21
RESULTS
###end title 21
###begin title 22
WTp53 downregulates APE1 mRNA and protein levels
###end title 22
###begin p 23
###xml 64 69 64 69 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(+/+)</sup>
###xml 84 89 84 89 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(&#8722;/&#8722;)</sup>
###xml 437 442 437 442 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(+/+)</sup>
###xml 450 458 450 458 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 536 541 536 541 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(&#8722;/&#8722;)</sup>
###xml 594 599 594 599 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(+/+)</sup>
###xml 757 762 757 762 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(+/+)</sup>
###xml 807 815 807 815 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 837 840 837 840 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p21</italic>
###xml 866 873 866 873 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1110 1115 1110 1115 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(+/+)</sup>
###xml 1156 1164 1156 1164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 1402 1407 1398 1403 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B49 B50 B51">49&#8211;51</xref>
###xml 1488 1493 1480 1485 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(+/+)</sup>
###xml 1501 1509 1493 1501 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 1560 1565 1552 1557 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(&#8722;/&#8722;)</sup>
###xml 1573 1581 1565 1573 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 1680 1689 1672 1681 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 1.</label>
###xml 1737 1742 1729 1734 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(+/+)</sup>
###xml 1771 1772 1763 1764 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 1828 1833 1820 1825 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(+/+)</sup>
###xml 1848 1853 1840 1845 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(&#8722;/&#8722;)</sup>
###xml 1974 1975 1964 1965 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 2002 2007 1992 1997 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(+/+)</sup>
###xml 2448 2449 2430 2431 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 2454 2455 2436 2437 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 2467 2472 2449 2454 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(+/+)</sup>
###xml 2478 2483 2460 2465 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(&#8722;/&#8722;)</sup>
###xml 2908 2909 2874 2875 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1689 2917 1681 2883 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="24">Repression of APE1 gene expression in HCT116 p53<sup>(+/+)</sup> cells after CPT treatment. (<bold>A</bold>) Real-time RT-PCR analysis of APE1 mRNA from HCT116 p53<sup>(+/+)</sup> and HCT116 p53<sup>(&#8722;/&#8722;)</sup> cells at indicated time points after CPT treatment. Results correspond to mean &#177; SD from three separate experiments. (<bold>B</bold>) After treating HCT116 p53<sup>(+/+)</sup> cells with CPT (200 nM), as described under Materials and Methods section, total lysates of cells harvested at the indicated times were analyzed for p53, APE1 and p21 levels by western blotting. &#946;-actin was used as the loading control. Right panel, graphical representation of APE1 protein level (normalized to &#946;-actin) at indicated time points after CPT treatment. Results correspond to mean &#177; SD from three separate experiments. (<bold>C</bold> and <bold>D</bold>) HCT116 p53<sup>(+/+)</sup>or p53<sup>(&#8722;/&#8722;)</sup> cells were treated with CPT (200 nM) for 24 h in the presence or absence of the p53 inhibitor PFT-&#945; and total lysates were analyzed for p53, APE1 and p21 levels by western blotting. &#946;-actin was used as the loading control. Right panel, graphical representation of APE1 protein level (normalized to &#946;-actin) after treatment with CPT or PFT-&#945;. Results correspond to mean &#177; SD from three separate experiments; *<italic>P</italic> &lt; 0.05.</p>
###xml 1689 2917 1681 2883 <caption xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="24">Repression of APE1 gene expression in HCT116 p53<sup>(+/+)</sup> cells after CPT treatment. (<bold>A</bold>) Real-time RT-PCR analysis of APE1 mRNA from HCT116 p53<sup>(+/+)</sup> and HCT116 p53<sup>(&#8722;/&#8722;)</sup> cells at indicated time points after CPT treatment. Results correspond to mean &#177; SD from three separate experiments. (<bold>B</bold>) After treating HCT116 p53<sup>(+/+)</sup> cells with CPT (200 nM), as described under Materials and Methods section, total lysates of cells harvested at the indicated times were analyzed for p53, APE1 and p21 levels by western blotting. &#946;-actin was used as the loading control. Right panel, graphical representation of APE1 protein level (normalized to &#946;-actin) at indicated time points after CPT treatment. Results correspond to mean &#177; SD from three separate experiments. (<bold>C</bold> and <bold>D</bold>) HCT116 p53<sup>(+/+)</sup>or p53<sup>(&#8722;/&#8722;)</sup> cells were treated with CPT (200 nM) for 24 h in the presence or absence of the p53 inhibitor PFT-&#945; and total lysates were analyzed for p53, APE1 and p21 levels by western blotting. &#946;-actin was used as the loading control. Right panel, graphical representation of APE1 protein level (normalized to &#946;-actin) after treatment with CPT or PFT-&#945;. Results correspond to mean &#177; SD from three separate experiments; *<italic>P</italic> &lt; 0.05.</p></caption>
###xml 2917 2917 2883 2883 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="gkm1173f1"/>
###xml 1680 2917 1672 2883 <fig xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="F1" position="float"><label>Figure 1.</label><caption><p textid="24">Repression of APE1 gene expression in HCT116 p53<sup>(+/+)</sup> cells after CPT treatment. (<bold>A</bold>) Real-time RT-PCR analysis of APE1 mRNA from HCT116 p53<sup>(+/+)</sup> and HCT116 p53<sup>(&#8722;/&#8722;)</sup> cells at indicated time points after CPT treatment. Results correspond to mean &#177; SD from three separate experiments. (<bold>B</bold>) After treating HCT116 p53<sup>(+/+)</sup> cells with CPT (200 nM), as described under Materials and Methods section, total lysates of cells harvested at the indicated times were analyzed for p53, APE1 and p21 levels by western blotting. &#946;-actin was used as the loading control. Right panel, graphical representation of APE1 protein level (normalized to &#946;-actin) at indicated time points after CPT treatment. Results correspond to mean &#177; SD from three separate experiments. (<bold>C</bold> and <bold>D</bold>) HCT116 p53<sup>(+/+)</sup>or p53<sup>(&#8722;/&#8722;)</sup> cells were treated with CPT (200 nM) for 24 h in the presence or absence of the p53 inhibitor PFT-&#945; and total lysates were analyzed for p53, APE1 and p21 levels by western blotting. &#946;-actin was used as the loading control. Right panel, graphical representation of APE1 protein level (normalized to &#946;-actin) after treatment with CPT or PFT-&#945;. Results correspond to mean &#177; SD from three separate experiments; *<italic>P</italic> &lt; 0.05.</p></caption><graphic xlink:href="gkm1173f1"/></fig>
We examined the effect of WTp53 on APE1 expression in HCT116 p53(+/+) and HCT116 p53(-/-) cell lines. To activate p53, these cells were treated with CPT, a DNA topoisomerase I inhibitor, and total RNA was isolated at the indicated times for quantitation of APE1 mRNA levels by real-time RT-PCR. We observed a significant decrease in the APE1 mRNA level at 18 h after treatment with CPT with simultaneous activation of WTp53 in HCT116 p53(+/+) cells (Figure 1A). Treatment with CPT also reduced APE1 mRNA level in p53-negative HCT116 p53(-/-) cells, although not to the same extent as in the p53(+/+) cells indicating a relationship between the p53 status and the downregulation of APE1 expression. Treatment with CPT also induced the p21 level in HCT116 p53(+/+) cells concomitant with enhanced p53 levels (Figure 1B). Activation of the p21 gene was used to monitor in vivo function of p53. Although a transient increase in the APE1 protein level was observed soon after (1 h) CPT treatment, consistent with the decreased APE1 mRNA level, the APE1 polypeptide level was also significantly reduced in HCT116 p53(+/+) cells at 18 h after treatment with CPT (Figure 1B, right panel). We further confirmed the role of p53 by treating cells with the water soluble p53 inhibitor PFT-alpha, which blocked activation of p53-regulated genes, including cyclin G, p21/Waf-1 and mdm2, and also inhibits apoptosis (49-51). Treatment with PFT-alpha attenuated APE1 repression after CPT treatment in p53(+/+) cells (Figure 1C), while it had no effect on the APE1 level in p53(-/-) cells (Figure 1D). Taken together, these results suggest that downregulation of APE1 expression is p53-dependent. Figure 1.Repression of APE1 gene expression in HCT116 p53(+/+) cells after CPT treatment. (A) Real-time RT-PCR analysis of APE1 mRNA from HCT116 p53(+/+) and HCT116 p53(-/-) cells at indicated time points after CPT treatment. Results correspond to mean +/- SD from three separate experiments. (B) After treating HCT116 p53(+/+) cells with CPT (200 nM), as described under Materials and Methods section, total lysates of cells harvested at the indicated times were analyzed for p53, APE1 and p21 levels by western blotting. beta-actin was used as the loading control. Right panel, graphical representation of APE1 protein level (normalized to beta-actin) at indicated time points after CPT treatment. Results correspond to mean +/- SD from three separate experiments. (C and D) HCT116 p53(+/+)or p53(-/-) cells were treated with CPT (200 nM) for 24 h in the presence or absence of the p53 inhibitor PFT-alpha and total lysates were analyzed for p53, APE1 and p21 levels by western blotting. beta-actin was used as the loading control. Right panel, graphical representation of APE1 protein level (normalized to beta-actin) after treatment with CPT or PFT-alpha. Results correspond to mean +/- SD from three separate experiments; *P < 0.05.
###end p 23
###begin p 24
###xml 48 53 48 53 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(+/+)</sup>
###xml 82 83 82 83 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 139 144 139 144 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(+/+)</sup>
###xml 159 164 159 164 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(&#8722;/&#8722;)</sup>
###xml 285 286 283 284 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 313 318 311 316 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(+/+)</sup>
###xml 759 760 749 750 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 765 766 755 756 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 778 783 768 773 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(+/+)</sup>
###xml 789 794 779 784 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(&#8722;/&#8722;)</sup>
###xml 1219 1220 1193 1194 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
Repression of APE1 gene expression in HCT116 p53(+/+) cells after CPT treatment. (A) Real-time RT-PCR analysis of APE1 mRNA from HCT116 p53(+/+) and HCT116 p53(-/-) cells at indicated time points after CPT treatment. Results correspond to mean +/- SD from three separate experiments. (B) After treating HCT116 p53(+/+) cells with CPT (200 nM), as described under Materials and Methods section, total lysates of cells harvested at the indicated times were analyzed for p53, APE1 and p21 levels by western blotting. beta-actin was used as the loading control. Right panel, graphical representation of APE1 protein level (normalized to beta-actin) at indicated time points after CPT treatment. Results correspond to mean +/- SD from three separate experiments. (C and D) HCT116 p53(+/+)or p53(-/-) cells were treated with CPT (200 nM) for 24 h in the presence or absence of the p53 inhibitor PFT-alpha and total lysates were analyzed for p53, APE1 and p21 levels by western blotting. beta-actin was used as the loading control. Right panel, graphical representation of APE1 protein level (normalized to beta-actin) after treatment with CPT or PFT-alpha. Results correspond to mean +/- SD from three separate experiments; *P < 0.05.
###end p 24
###begin p 25
###xml 376 384 376 384 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
###xml 477 485 477 485 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
###xml 626 634 626 634 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
###xml 744 752 744 752 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
###xml 957 960 957 960 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cis</italic>
###xml 971 979 971 979 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
###xml 1072 1081 1072 1081 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 2.</label>
###xml 1174 1175 1174 1175 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 1529 1530 1521 1522 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 1591 1596 1583 1588 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(&#8722;/&#8722;)</sup>
###xml 1781 1782 1767 1768 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 1952 1953 1938 1939 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 1998 2000 1984 1986 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">32</sup>
###xml 2085 2086 2071 2072 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1081 2094 1081 2080 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="26">Decreased APE1 protein and mRNA levels after ectopic expression of WTp53 in p53 null cells. (<bold>A</bold>) Total cell extracts were analyzed for p53, APE1 and p21 levels by western blotting. &#946;-actin was used as the loading control. Right panel, graphical representation of APE1 protein level (normalized to &#946;-actin) after transfection with various amounts of WTp53 expression plasmid. Results correspond to mean &#177; SD from three separate experiments. (<bold>B</bold>) Real-time RT-PCR analysis of APE1 mRNA levels in HCT116 p53<sup>(&#8722;/&#8722;)</sup>cells transfected with various amounts of WTp53 expression plasmid and incubated with PFT-&#945; or vehicle for 48 h. Results correspond to mean &#177; SD from three separate experiments. (<bold>C</bold>) Western analysis of p53 and p21 levels in nuclear fraction in p53 null cells after ectopic expression of WTp53. Lamin B was used for nuclear extracts loading control. (<bold>D</bold>) EMSA of nuclear extracts used in (C) using <sup>32</sup>P-labeled duplex oligo from p21 promoter containing consensus p53-binding sequence; *<italic>P</italic> &lt; 0.05.</p>
###xml 1081 2094 1081 2080 <caption xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="26">Decreased APE1 protein and mRNA levels after ectopic expression of WTp53 in p53 null cells. (<bold>A</bold>) Total cell extracts were analyzed for p53, APE1 and p21 levels by western blotting. &#946;-actin was used as the loading control. Right panel, graphical representation of APE1 protein level (normalized to &#946;-actin) after transfection with various amounts of WTp53 expression plasmid. Results correspond to mean &#177; SD from three separate experiments. (<bold>B</bold>) Real-time RT-PCR analysis of APE1 mRNA levels in HCT116 p53<sup>(&#8722;/&#8722;)</sup>cells transfected with various amounts of WTp53 expression plasmid and incubated with PFT-&#945; or vehicle for 48 h. Results correspond to mean &#177; SD from three separate experiments. (<bold>C</bold>) Western analysis of p53 and p21 levels in nuclear fraction in p53 null cells after ectopic expression of WTp53. Lamin B was used for nuclear extracts loading control. (<bold>D</bold>) EMSA of nuclear extracts used in (C) using <sup>32</sup>P-labeled duplex oligo from p21 promoter containing consensus p53-binding sequence; *<italic>P</italic> &lt; 0.05.</p></caption>
###xml 2094 2094 2080 2080 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="gkm1173f2"/>
###xml 1072 2094 1072 2080 <fig xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="F2" position="float"><label>Figure 2.</label><caption><p textid="26">Decreased APE1 protein and mRNA levels after ectopic expression of WTp53 in p53 null cells. (<bold>A</bold>) Total cell extracts were analyzed for p53, APE1 and p21 levels by western blotting. &#946;-actin was used as the loading control. Right panel, graphical representation of APE1 protein level (normalized to &#946;-actin) after transfection with various amounts of WTp53 expression plasmid. Results correspond to mean &#177; SD from three separate experiments. (<bold>B</bold>) Real-time RT-PCR analysis of APE1 mRNA levels in HCT116 p53<sup>(&#8722;/&#8722;)</sup>cells transfected with various amounts of WTp53 expression plasmid and incubated with PFT-&#945; or vehicle for 48 h. Results correspond to mean &#177; SD from three separate experiments. (<bold>C</bold>) Western analysis of p53 and p21 levels in nuclear fraction in p53 null cells after ectopic expression of WTp53. Lamin B was used for nuclear extracts loading control. (<bold>D</bold>) EMSA of nuclear extracts used in (C) using <sup>32</sup>P-labeled duplex oligo from p21 promoter containing consensus p53-binding sequence; *<italic>P</italic> &lt; 0.05.</p></caption><graphic xlink:href="gkm1173f2"/></fig>
To further confirm that WTp53 acts as a negative regulator of APE1 expression, we investigated the effect of WTp53 overexpression on the APE1 protein and mRNA levels in HCT116 p53 null cells. Various amounts of expression plasmid for WTp53 were used for transfection of p53 null cells, and the expression of p53 and p21 was confirmed by western analysis of the cell extracts (Figure 2A). Overexpression of p53 decreased APE1 mRNA and protein levels in a dose-dependent manner (Figure 2A and B). To confirm that ectopic p53 was transcriptionally active, we measured the p21 levels in nuclear extracts of p53-transfected cells (Figure 2C), and its binding to double-stranded oligonucleotides containing the p53-binding motif of the p21 promoter. Figure 2C shows predominant localization of p53 in nuclear fraction of cells after ectopic expression of WTp53. EMSA of the same extract confirmed the presence of WTp53 which formed a shifted complex with the p53 cis sequence (Figure 2D). Together, these results further confirm that p53 acts as a repressor of APE1 expression. Figure 2.Decreased APE1 protein and mRNA levels after ectopic expression of WTp53 in p53 null cells. (A) Total cell extracts were analyzed for p53, APE1 and p21 levels by western blotting. beta-actin was used as the loading control. Right panel, graphical representation of APE1 protein level (normalized to beta-actin) after transfection with various amounts of WTp53 expression plasmid. Results correspond to mean +/- SD from three separate experiments. (B) Real-time RT-PCR analysis of APE1 mRNA levels in HCT116 p53(-/-)cells transfected with various amounts of WTp53 expression plasmid and incubated with PFT-alpha or vehicle for 48 h. Results correspond to mean +/- SD from three separate experiments. (C) Western analysis of p53 and p21 levels in nuclear fraction in p53 null cells after ectopic expression of WTp53. Lamin B was used for nuclear extracts loading control. (D) EMSA of nuclear extracts used in (C) using 32P-labeled duplex oligo from p21 promoter containing consensus p53-binding sequence; *P < 0.05.
###end p 25
###begin p 26
###xml 93 94 93 94 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 448 449 440 441 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 510 515 502 507 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(&#8722;/&#8722;)</sup>
###xml 700 701 686 687 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 871 872 857 858 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 917 919 903 905 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">32</sup>
###xml 1004 1005 990 991 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
Decreased APE1 protein and mRNA levels after ectopic expression of WTp53 in p53 null cells. (A) Total cell extracts were analyzed for p53, APE1 and p21 levels by western blotting. beta-actin was used as the loading control. Right panel, graphical representation of APE1 protein level (normalized to beta-actin) after transfection with various amounts of WTp53 expression plasmid. Results correspond to mean +/- SD from three separate experiments. (B) Real-time RT-PCR analysis of APE1 mRNA levels in HCT116 p53(-/-)cells transfected with various amounts of WTp53 expression plasmid and incubated with PFT-alpha or vehicle for 48 h. Results correspond to mean +/- SD from three separate experiments. (C) Western analysis of p53 and p21 levels in nuclear fraction in p53 null cells after ectopic expression of WTp53. Lamin B was used for nuclear extracts loading control. (D) EMSA of nuclear extracts used in (C) using 32P-labeled duplex oligo from p21 promoter containing consensus p53-binding sequence; *P < 0.05.
###end p 26
###begin title 27
APE1 promoter activity is repressed by WTp53, but not by mutant p53
###end title 27
###begin p 28
###xml 416 421 416 421 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(&#8722;/&#8722;)</sup>
###xml 565 573 565 573 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Figure 3</xref>
###xml 687 695 687 695 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Figure 3</xref>
###xml 1075 1083 1075 1083 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Figure 3</xref>
###xml 1746 1748 1743 1745 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 1749 1751 1746 1748 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 1806 1809 1803 1806 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cis</italic>
###xml 1866 1868 1863 1865 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B52">52</xref>
###xml 2093 2101 2078 2086 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Figure 3</xref>
###xml 2128 2133 2113 2118 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(&#8722;/&#8722;)</sup>
###xml 2330 2338 2315 2323 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Figure 3</xref>
###xml 2456 2465 2441 2450 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 3.</label>
###xml 2529 2530 2514 2515 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 2535 2540 2520 2525 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(&#8722;/&#8722;)</sup>
###xml 2890 2891 2872 2873 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 2974 2975 2956 2957 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 2980 2985 2962 2967 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(&#8722;/&#8722;)</sup>
###xml 3172 3173 3153 3154 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 3178 3183 3159 3164 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(&#8722;/&#8722;)</sup>
###xml 3355 3357 3334 3336 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 3358 3360 3337 3339 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 3432 3433 3411 3412 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</bold>
###xml 3504 3505 3483 3484 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 3516 3517 3495 3496 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 2465 3526 2450 3505 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="29">Inhibition of APE1 promoter activity by WT but not mutant p53. (<bold>A</bold>) p53<sup>(&#8722;/&#8722;)</sup> cells were transiently transfected with (0.5 &#956;g) of APE1 promoter&#8211;luciferase plasmid (&#8722;4500/+65) and various amounts of WTp53 expression plasmid or control vector. Luciferase activity was measured at 48 h after transfection and normalized for the amount of protein. The mean &#177; SD of five independent experiments performed in duplicate is shown. (<bold>B</bold>) Western analysis of the p53 level in the transfected cell extracts used in (A). (<bold>C</bold>) p53<sup>(&#8722;/&#8722;)</sup> cells were cotransfected with (0.5 &#956;g) of p21 promoter&#8211;luciferase plasmid and WTp53. Luciferase activity was measured 48 h after transfection and normalized for the amount of protein. (<bold>D</bold>) p53<sup>(&#8722;/&#8722;)</sup> cells were transiently transfected with (0.5 &#956;g) of APE1 promoter&#8211;luciferase plasmid (&#8722;4500/+65) and 0.05 &#956;g of expression plasmid encoding WTp53 or mutant p53 (V143A) (<xref ref-type="bibr" rid="B22">22</xref>,<xref ref-type="bibr" rid="B23">23</xref>) or equivalent amount of empty vector. Other details are given above. (<bold>E</bold>) Western analysis of WT and mutant p53 in cells lysates used in (D); *<italic>P</italic> &lt; 0.05; **<italic>P</italic> &lt; 0.001.</p>
###xml 2465 3526 2450 3505 <caption xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="29">Inhibition of APE1 promoter activity by WT but not mutant p53. (<bold>A</bold>) p53<sup>(&#8722;/&#8722;)</sup> cells were transiently transfected with (0.5 &#956;g) of APE1 promoter&#8211;luciferase plasmid (&#8722;4500/+65) and various amounts of WTp53 expression plasmid or control vector. Luciferase activity was measured at 48 h after transfection and normalized for the amount of protein. The mean &#177; SD of five independent experiments performed in duplicate is shown. (<bold>B</bold>) Western analysis of the p53 level in the transfected cell extracts used in (A). (<bold>C</bold>) p53<sup>(&#8722;/&#8722;)</sup> cells were cotransfected with (0.5 &#956;g) of p21 promoter&#8211;luciferase plasmid and WTp53. Luciferase activity was measured 48 h after transfection and normalized for the amount of protein. (<bold>D</bold>) p53<sup>(&#8722;/&#8722;)</sup> cells were transiently transfected with (0.5 &#956;g) of APE1 promoter&#8211;luciferase plasmid (&#8722;4500/+65) and 0.05 &#956;g of expression plasmid encoding WTp53 or mutant p53 (V143A) (<xref ref-type="bibr" rid="B22">22</xref>,<xref ref-type="bibr" rid="B23">23</xref>) or equivalent amount of empty vector. Other details are given above. (<bold>E</bold>) Western analysis of WT and mutant p53 in cells lysates used in (D); *<italic>P</italic> &lt; 0.05; **<italic>P</italic> &lt; 0.001.</p></caption>
###xml 3526 3526 3505 3505 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="gkm1173f3"/>
###xml 2456 3526 2441 3505 <fig xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="F3" position="float"><label>Figure 3.</label><caption><p textid="29">Inhibition of APE1 promoter activity by WT but not mutant p53. (<bold>A</bold>) p53<sup>(&#8722;/&#8722;)</sup> cells were transiently transfected with (0.5 &#956;g) of APE1 promoter&#8211;luciferase plasmid (&#8722;4500/+65) and various amounts of WTp53 expression plasmid or control vector. Luciferase activity was measured at 48 h after transfection and normalized for the amount of protein. The mean &#177; SD of five independent experiments performed in duplicate is shown. (<bold>B</bold>) Western analysis of the p53 level in the transfected cell extracts used in (A). (<bold>C</bold>) p53<sup>(&#8722;/&#8722;)</sup> cells were cotransfected with (0.5 &#956;g) of p21 promoter&#8211;luciferase plasmid and WTp53. Luciferase activity was measured 48 h after transfection and normalized for the amount of protein. (<bold>D</bold>) p53<sup>(&#8722;/&#8722;)</sup> cells were transiently transfected with (0.5 &#956;g) of APE1 promoter&#8211;luciferase plasmid (&#8722;4500/+65) and 0.05 &#956;g of expression plasmid encoding WTp53 or mutant p53 (V143A) (<xref ref-type="bibr" rid="B22">22</xref>,<xref ref-type="bibr" rid="B23">23</xref>) or equivalent amount of empty vector. Other details are given above. (<bold>E</bold>) Western analysis of WT and mutant p53 in cells lysates used in (D); *<italic>P</italic> &lt; 0.05; **<italic>P</italic> &lt; 0.001.</p></caption><graphic xlink:href="gkm1173f3"/></fig>
###xml 1114 1117 <span type="species:ncbi:12305?0.03296277145811789|species:ncbi:36410?3.8779731127197516E-4">CMV</span>
To determine whether p53-mediated downregulation of APE1 occurred at the promoter level, we examined the effect of p53 overexpression on APE1 promoter-dependent luciferase activity in a transient reporter expression assay. We cotransfected an APE1 promoter luciferase reporter construct (-4000/+65 APE1-Luc, containing the APE1 promoter sequence from -4000 to +65 bp) and the WTp53 expression plasmid into HCT116 p53(-/-) cells. Ectopic expression of WTp53 induced a dose-dependent decrease in APE1 promoter activity (up to 250-fold compared to the vector control, Figure 3A). Increase in p53 expression was confirmed by western analysis of the same cells extract with antip53 antibody (Figure 3B). Because p53 is an activator of the p21 gene, we simultaneously examined the effect of ectopic expression of p53 on p21 promoter-dependent luciferase activity. The increase in p21 promoter-dependent luciferase activity with increasing amounts of input p53 plasmid indicated that the inhibitory effect of p53 on APE1 promoter was not due to general inhibition of transcription (Figure 3C). Moreover, we observed that CMV promoter-dependent beta-galactosidase and thymidine kinase promoter-dependent renilla-luciferase (pRL-TK, Promega) levels were also increased due to overexpression of WTp53 for unknown reasons (data not shown). We thus could not therefore use these reporter plasmids for normalizing transfection efficiency. In any case, our results indicate that the p53-dependent repression is APE1 promoter specific, and not a general phenomenon. We also examined the effects of two p53 point mutants on APE1 promoter activity namely, V143A, a missense mutation which inactivates p53's sequence-specific DNA binding, and a Leu22Gln Trp23Ser (22,23), double mutant which retains the ability to bind p53-cis sequences but lacks transcriptional activation ability (52). Overexpression of WTp53 significantly decreased luciferase activity under the control of the APE1 promoter (reaching up to approximately60-fold with 50 ng of WTp53), while the mutants had no significant inhibitory effect (Figure 3D). Western analysis of p53(-/-) cells lysates transiently transfected with p53 expression plasmids revealed that the p53 mutant polypeptides were more stable than the WT protein, and were present at higher levels (2- to 3-fold, Figure 3E). These results indicate that despite these higher levels, mutant p53 could not inhibit the APE1 promoter activity. Figure 3.Inhibition of APE1 promoter activity by WT but not mutant p53. (A) p53(-/-) cells were transiently transfected with (0.5 mug) of APE1 promoter-luciferase plasmid (-4500/+65) and various amounts of WTp53 expression plasmid or control vector. Luciferase activity was measured at 48 h after transfection and normalized for the amount of protein. The mean +/- SD of five independent experiments performed in duplicate is shown. (B) Western analysis of the p53 level in the transfected cell extracts used in (A). (C) p53(-/-) cells were cotransfected with (0.5 mug) of p21 promoter-luciferase plasmid and WTp53. Luciferase activity was measured 48 h after transfection and normalized for the amount of protein. (D) p53(-/-) cells were transiently transfected with (0.5 mug) of APE1 promoter-luciferase plasmid (-4500/+65) and 0.05 mug of expression plasmid encoding WTp53 or mutant p53 (V143A) (22,23) or equivalent amount of empty vector. Other details are given above. (E) Western analysis of WT and mutant p53 in cells lysates used in (D); *P < 0.05; **P < 0.001.
###end p 28
###begin p 29
###xml 64 65 64 65 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 70 75 70 75 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(&#8722;/&#8722;)</sup>
###xml 425 426 422 423 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 509 510 506 507 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 515 520 512 517 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(&#8722;/&#8722;)</sup>
###xml 707 708 703 704 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">D</bold>
###xml 713 718 709 714 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(&#8722;/&#8722;)</sup>
###xml 890 892 884 886 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 893 895 887 889 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 967 968 961 962 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E</bold>
###xml 1039 1040 1033 1034 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1051 1052 1045 1046 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
Inhibition of APE1 promoter activity by WT but not mutant p53. (A) p53(-/-) cells were transiently transfected with (0.5 mug) of APE1 promoter-luciferase plasmid (-4500/+65) and various amounts of WTp53 expression plasmid or control vector. Luciferase activity was measured at 48 h after transfection and normalized for the amount of protein. The mean +/- SD of five independent experiments performed in duplicate is shown. (B) Western analysis of the p53 level in the transfected cell extracts used in (A). (C) p53(-/-) cells were cotransfected with (0.5 mug) of p21 promoter-luciferase plasmid and WTp53. Luciferase activity was measured 48 h after transfection and normalized for the amount of protein. (D) p53(-/-) cells were transiently transfected with (0.5 mug) of APE1 promoter-luciferase plasmid (-4500/+65) and 0.05 mug of expression plasmid encoding WTp53 or mutant p53 (V143A) (22,23) or equivalent amount of empty vector. Other details are given above. (E) Western analysis of WT and mutant p53 in cells lysates used in (D); *P < 0.05; **P < 0.001.
###end p 29
###begin title 30
###xml 33 36 33 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cis</italic>
Identification of p53-responsive cis element(s) in APE1 promoter
###end title 30
###begin p 31
###xml 16 19 16 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cis</italic>
###xml 329 331 329 331 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 423 426 423 426 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cis</italic>
###xml 487 492 487 492 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(&#8722;/&#8722;)</sup>
###xml 736 744 724 732 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Figure 4</xref>
###xml 856 858 844 846 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 994 1002 982 990 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Figure 4</xref>
###xml 1006 1015 994 1003 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 4.</label>
###xml 1068 1069 1056 1057 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 1222 1223 1210 1211 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 1228 1233 1216 1221 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(&#8722;/&#8722;)</sup>
###xml 1438 1439 1425 1426 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1015 1447 1003 1434 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="32">Effect of WTp53 on APE1 promoter reporter activity. (<bold>A</bold>) Basal promoter activity of APE1 promoter luciferase constructs containing &#8722;4500 or &#8722;1800 bp of APE1 promoter sequences linked to the luciferase gene. (<bold>B</bold>) p53<sup>(&#8722;/&#8722;)</sup> cells were transiently transfected with 0.5 &#956;g of APE1 promoter&#8211;luciferase plasmid (&#8722;1800/+65) and WTp53 or control vector as before. Luciferase activity was measured 48 h after transfection as before; *<italic>P</italic> &lt; 0.05.</p>
###xml 1015 1447 1003 1434 <caption xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="32">Effect of WTp53 on APE1 promoter reporter activity. (<bold>A</bold>) Basal promoter activity of APE1 promoter luciferase constructs containing &#8722;4500 or &#8722;1800 bp of APE1 promoter sequences linked to the luciferase gene. (<bold>B</bold>) p53<sup>(&#8722;/&#8722;)</sup> cells were transiently transfected with 0.5 &#956;g of APE1 promoter&#8211;luciferase plasmid (&#8722;1800/+65) and WTp53 or control vector as before. Luciferase activity was measured 48 h after transfection as before; *<italic>P</italic> &lt; 0.05.</p></caption>
###xml 1447 1447 1434 1434 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="gkm1173f4"/>
###xml 1006 1447 994 1434 <fig xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="F4" position="float"><label>Figure 4.</label><caption><p textid="32">Effect of WTp53 on APE1 promoter reporter activity. (<bold>A</bold>) Basal promoter activity of APE1 promoter luciferase constructs containing &#8722;4500 or &#8722;1800 bp of APE1 promoter sequences linked to the luciferase gene. (<bold>B</bold>) p53<sup>(&#8722;/&#8722;)</sup> cells were transiently transfected with 0.5 &#956;g of APE1 promoter&#8211;luciferase plasmid (&#8722;1800/+65) and WTp53 or control vector as before. Luciferase activity was measured 48 h after transfection as before; *<italic>P</italic> &lt; 0.05.</p></caption><graphic xlink:href="gkm1173f4"/></fig>
To identify the cis element(s) responsible for p53-mediated downregulation of the APE1 promoter, we carried out promoter deletion analysis. We have shown earlier that the APE1 promoter contains multiple negative regulatory and enhancer elements, including two nCaRE-B elements upstream (-4000 to -1800 bp) of the basal promoter (15). To test whether p53-induced repression of APE1 promoter activity is mediated through the cis elements located in this region, we cotransfected HCT116 p53(-/-) cells with WTp53 and the reporter plasmid containing -1800 to +65 bp (-1800/+65 APE1-Luc) of the APE1 promoter. Deletion of the promoter sequence from -4000 to -1800 bp significantly increased the basal promoter activity (approximately9-fold, Figure 4A), confirming our earlier observation about the presence of negative regulatory elements within this sequence (15). Furthermore, ectopic expression of WTp53 caused a decrease in the promoter (-1800/+65 APE1-Luc) activity in a dose-dependent manner (Figure 4B). Figure 4.Effect of WTp53 on APE1 promoter reporter activity. (A) Basal promoter activity of APE1 promoter luciferase constructs containing -4500 or -1800 bp of APE1 promoter sequences linked to the luciferase gene. (B) p53(-/-) cells were transiently transfected with 0.5 mug of APE1 promoter-luciferase plasmid (-1800/+65) and WTp53 or control vector as before. Luciferase activity was measured 48 h after transfection as before; *P < 0.05.
###end p 31
###begin p 32
###xml 53 54 53 54 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 207 208 207 208 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 213 218 213 218 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(&#8722;/&#8722;)</sup>
###xml 423 424 422 423 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
Effect of WTp53 on APE1 promoter reporter activity. (A) Basal promoter activity of APE1 promoter luciferase constructs containing -4500 or -1800 bp of APE1 promoter sequences linked to the luciferase gene. (B) p53(-/-) cells were transiently transfected with 0.5 mug of APE1 promoter-luciferase plasmid (-1800/+65) and WTp53 or control vector as before. Luciferase activity was measured 48 h after transfection as before; *P < 0.05.
###end p 32
###begin p 33
###xml 174 182 174 182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Figure 5</xref>
###xml 434 442 434 442 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Figure 5</xref>
###xml 775 783 763 771 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Figure 5</xref>
###xml 863 871 851 859 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Figure 5</xref>
###xml 914 922 902 910 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Figure 5</xref>
###xml 946 949 934 937 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cis</italic>
###xml 1137 1145 1125 1133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Figure 5</xref>
###xml 1255 1263 1243 1251 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Figure 5</xref>
###xml 1291 1294 1279 1282 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cis</italic>
###xml 1394 1403 1382 1391 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 5.</label>
###xml 1404 1405 1392 1393 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 1640 1641 1628 1629 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 1646 1651 1634 1639 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(&#8722;/&#8722;)</sup>
###xml 2147 2148 2131 2132 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1403 2157 1391 2141 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="34">(<bold>A</bold>) Schematic diagram of the APE1 promoter 5&#8242; regulatory region showing the location of DNA fragments cloned upstream of the luciferase-coding region. The nucleotides are numbered 5&#8242;(&#8722;) and 3&#8242;(+) from the transcription start site (+1). (<bold>B</bold>) p53<sup>(&#8722;/&#8722;)</sup> cells were cotransfected with expression plasmid for WTp53 (0.1 &#956;g) or empty vector and individually for APE1 promoter&#8211;reporter plasmids (0.5 &#956;g) 1&#8211;8, as indicated in (A). Luciferase activity was measured 48 h after transfection and normalized for the amount of protein. Fold inhibition was calculated as the ratio of luciferase activity from empty vector transfected versus p53-transfected cells; the results represent the mean &#177; SD in five independent experiments performed in duplicate; *<italic>P</italic> &lt; 0.001.</p>
###xml 1403 2157 1391 2141 <caption xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="34">(<bold>A</bold>) Schematic diagram of the APE1 promoter 5&#8242; regulatory region showing the location of DNA fragments cloned upstream of the luciferase-coding region. The nucleotides are numbered 5&#8242;(&#8722;) and 3&#8242;(+) from the transcription start site (+1). (<bold>B</bold>) p53<sup>(&#8722;/&#8722;)</sup> cells were cotransfected with expression plasmid for WTp53 (0.1 &#956;g) or empty vector and individually for APE1 promoter&#8211;reporter plasmids (0.5 &#956;g) 1&#8211;8, as indicated in (A). Luciferase activity was measured 48 h after transfection and normalized for the amount of protein. Fold inhibition was calculated as the ratio of luciferase activity from empty vector transfected versus p53-transfected cells; the results represent the mean &#177; SD in five independent experiments performed in duplicate; *<italic>P</italic> &lt; 0.001.</p></caption>
###xml 2157 2157 2141 2141 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="gkm1173f5"/>
###xml 1394 2157 1382 2141 <fig xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="F5" position="float"><label>Figure 5.</label><caption><p textid="34">(<bold>A</bold>) Schematic diagram of the APE1 promoter 5&#8242; regulatory region showing the location of DNA fragments cloned upstream of the luciferase-coding region. The nucleotides are numbered 5&#8242;(&#8722;) and 3&#8242;(+) from the transcription start site (+1). (<bold>B</bold>) p53<sup>(&#8722;/&#8722;)</sup> cells were cotransfected with expression plasmid for WTp53 (0.1 &#956;g) or empty vector and individually for APE1 promoter&#8211;reporter plasmids (0.5 &#956;g) 1&#8211;8, as indicated in (A). Luciferase activity was measured 48 h after transfection and normalized for the amount of protein. Fold inhibition was calculated as the ratio of luciferase activity from empty vector transfected versus p53-transfected cells; the results represent the mean &#177; SD in five independent experiments performed in duplicate; *<italic>P</italic> &lt; 0.001.</p></caption><graphic xlink:href="gkm1173f5"/></fig>
We then carried out detailed mapping of the p53 regulatory sequence by using a series of 5' promoter deletion constructs. DNA fragments of the 5' regulatory region (shown in Figure 5A) were cloned upstream of the luciferase coding region and their promoter activity was determined by cotransfection as before. All deletion constructs except 7 and 8 showed basal promoter activity that was abolished by deleting residues -143 to -118 (Figure 5A and B) indicating that the sequence upstream of -118 is required for basal promoter activity. Although deletion of -4000 to -1800 decreased p53-mediated downregulation of promoter activity by approximately1.5-fold, luciferase activity of all the deletion constructs was significantly downregulated after cotransfection with WTp53 (Figure 5B). However, elimination of the sequence from -184 to -143 (construct number 6, Figure 5A) abolished the inhibitory effect of p53 (Figure 5B), indicating that the cis element involved in p53-dependent repression is localized within this sequence. Furthermore, deletion of the +65 bp region downstream to the transcription start site (construct number 5, Figure 5A) had no effect on p53-mediated repression, indicating that these sequences are not required for repression (Figure 5B). Thus the p53-responsive cis elements appeared to be located within the proximal region (-184 to -143 bp) of the APE1 promoter. Figure 5.(A) Schematic diagram of the APE1 promoter 5' regulatory region showing the location of DNA fragments cloned upstream of the luciferase-coding region. The nucleotides are numbered 5'(-) and 3'(+) from the transcription start site (+1). (B) p53(-/-) cells were cotransfected with expression plasmid for WTp53 (0.1 mug) or empty vector and individually for APE1 promoter-reporter plasmids (0.5 mug) 1-8, as indicated in (A). Luciferase activity was measured 48 h after transfection and normalized for the amount of protein. Fold inhibition was calculated as the ratio of luciferase activity from empty vector transfected versus p53-transfected cells; the results represent the mean +/- SD in five independent experiments performed in duplicate; *P < 0.001.
###end p 33
###begin p 34
###xml 1 2 1 2 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 237 238 237 238 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 243 248 243 248 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(&#8722;/&#8722;)</sup>
###xml 744 745 740 741 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
(A) Schematic diagram of the APE1 promoter 5' regulatory region showing the location of DNA fragments cloned upstream of the luciferase-coding region. The nucleotides are numbered 5'(-) and 3'(+) from the transcription start site (+1). (B) p53(-/-) cells were cotransfected with expression plasmid for WTp53 (0.1 mug) or empty vector and individually for APE1 promoter-reporter plasmids (0.5 mug) 1-8, as indicated in (A). Luciferase activity was measured 48 h after transfection and normalized for the amount of protein. Fold inhibition was calculated as the ratio of luciferase activity from empty vector transfected versus p53-transfected cells; the results represent the mean +/- SD in five independent experiments performed in duplicate; *P < 0.001.
###end p 34
###begin title 35
###xml 51 59 51 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
Lack of direct binding of p53 to the APE1 promoter in vitro
###end title 35
###begin p 36
###xml 40 43 40 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cis</italic>
###xml 496 499 496 499 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cis</italic>
###xml 580 588 580 588 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F6">Figure 6</xref>
###xml 759 767 759 767 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 769 778 769 778 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 6.</label>
###xml 793 800 793 800 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 841 842 841 842 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 903 905 903 905 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">32</sup>
###xml 1092 1093 1092 1093 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 1098 1103 1098 1103 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(+/+)</sup>
###xml 778 1502 778 1502 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="37">ChIP assay for <italic>in vivo</italic> association of p53 with APE1 promoter. (<bold>A</bold>) EMSA of purified p53 (60 ng, lane 4; 120 ng, lane 5) using <sup>32</sup>P-labeled duplex oligo corresponding to the bases (&#8722;184 to 142) from the APE1 promoter sequence or containing consensus p53-binding sequence from the p21 promoter (lane 2) as a control. (<bold>B</bold>) p53<sup>(+/+)</sup> cells were treated with CPT for 9 h, the protein&#8211;DNA was crosslinked, and ChIP assays performed as described in Materials and Methods section. Immunoprecipitated APE1 promoter with the indicated antibody was amplified with primers as described in Materials and Methods section. Left panel, schematic diagram of the APE1 promoter showing the relative position of PCR primers used in the ChIP assays.</p>
###xml 778 1502 778 1502 <caption xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="37">ChIP assay for <italic>in vivo</italic> association of p53 with APE1 promoter. (<bold>A</bold>) EMSA of purified p53 (60 ng, lane 4; 120 ng, lane 5) using <sup>32</sup>P-labeled duplex oligo corresponding to the bases (&#8722;184 to 142) from the APE1 promoter sequence or containing consensus p53-binding sequence from the p21 promoter (lane 2) as a control. (<bold>B</bold>) p53<sup>(+/+)</sup> cells were treated with CPT for 9 h, the protein&#8211;DNA was crosslinked, and ChIP assays performed as described in Materials and Methods section. Immunoprecipitated APE1 promoter with the indicated antibody was amplified with primers as described in Materials and Methods section. Left panel, schematic diagram of the APE1 promoter showing the relative position of PCR primers used in the ChIP assays.</p></caption>
###xml 1502 1502 1502 1502 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="gkm1173f6"/>
###xml 769 1502 769 1502 <fig xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="F6" position="float"><label>Figure 6.</label><caption><p textid="37">ChIP assay for <italic>in vivo</italic> association of p53 with APE1 promoter. (<bold>A</bold>) EMSA of purified p53 (60 ng, lane 4; 120 ng, lane 5) using <sup>32</sup>P-labeled duplex oligo corresponding to the bases (&#8722;184 to 142) from the APE1 promoter sequence or containing consensus p53-binding sequence from the p21 promoter (lane 2) as a control. (<bold>B</bold>) p53<sup>(+/+)</sup> cells were treated with CPT for 9 h, the protein&#8211;DNA was crosslinked, and ChIP assays performed as described in Materials and Methods section. Immunoprecipitated APE1 promoter with the indicated antibody was amplified with primers as described in Materials and Methods section. Left panel, schematic diagram of the APE1 promoter showing the relative position of PCR primers used in the ChIP assays.</p></caption><graphic xlink:href="gkm1173f6"/></fig>
To identify the putative p53-responsive cis element(s) in the 41 bp (-184 to -143) APE1 promoter sequence, we performed a computer search for potential transcription factor binding sites. Putative binding sites were identified one each for Sp1 and upstream factor (USF); however, no consensus p53-binding site could be shown even allowing for two mismatches. Nevertheless, we tested for a potential binding site for p53 in this 41 bp sequence by EMSA using a recombinant p53 polypeptide. The p53 cis element present in the p21 promoter was used as a positive control. As shown in Figure 6A, purified p53 can bind to the p21 promoter (lane 2), but not to the APE1 promoter sequence (lanes 4 and 5), indicating a lack of direct p53 binding to the APE1 promoter in vitro. Figure 6.ChIP assay for in vivo association of p53 with APE1 promoter. (A) EMSA of purified p53 (60 ng, lane 4; 120 ng, lane 5) using 32P-labeled duplex oligo corresponding to the bases (-184 to 142) from the APE1 promoter sequence or containing consensus p53-binding sequence from the p21 promoter (lane 2) as a control. (B) p53(+/+) cells were treated with CPT for 9 h, the protein-DNA was crosslinked, and ChIP assays performed as described in Materials and Methods section. Immunoprecipitated APE1 promoter with the indicated antibody was amplified with primers as described in Materials and Methods section. Left panel, schematic diagram of the APE1 promoter showing the relative position of PCR primers used in the ChIP assays.
###end p 36
###begin p 37
###xml 15 22 15 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 63 64 63 64 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 125 127 125 127 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">32</sup>
###xml 314 315 314 315 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 320 325 320 325 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(+/+)</sup>
ChIP assay for in vivo association of p53 with APE1 promoter. (A) EMSA of purified p53 (60 ng, lane 4; 120 ng, lane 5) using 32P-labeled duplex oligo corresponding to the bases (-184 to 142) from the APE1 promoter sequence or containing consensus p53-binding sequence from the p21 promoter (lane 2) as a control. (B) p53(+/+) cells were treated with CPT for 9 h, the protein-DNA was crosslinked, and ChIP assays performed as described in Materials and Methods section. Immunoprecipitated APE1 promoter with the indicated antibody was amplified with primers as described in Materials and Methods section. Left panel, schematic diagram of the APE1 promoter showing the relative position of PCR primers used in the ChIP assays.
###end p 37
###begin title 38
Recruitment of p53 to the APE1 promoter is induced by cellular stress
###end title 38
###begin p 39
###xml 206 213 206 213 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 215 217 215 217 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B41">41</xref>
###xml 223 228 223 228 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(+/+)</sup>
###xml 236 241 236 241 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(&#8722;/&#8722;)</sup>
###xml 854 862 854 862 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F6">Figure 6</xref>
###xml 1007 1014 1007 1014 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 1028 1033 1028 1033 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(+/+)</sup>
###xml 1262 1267 1262 1267 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(&#8722;/&#8722;)</sup>
###xml 1275 1283 1275 1283 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F6">Figure 6</xref>
###xml 1467 1475 1467 1475 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F6">Figure 6</xref>
###xml 1573 1575 1573 1575 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B53">53</xref>
###xml 1715 1723 1715 1723 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F6">Figure 6</xref>
###xml 1836 1841 1836 1841 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(+/+)</sup>
###xml 1849 1854 1849 1854 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(&#8722;/&#8722;)</sup>
###xml 2052 2060 2052 2060 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F6">Figure 6</xref>
###xml 2149 2154 2149 2154 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(+/+)</sup>
###xml 2166 2171 2166 2171 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(&#8722;/&#8722;)</sup>
###xml 2232 2239 2232 2239 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 2375 2382 2375 2382 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 2355 2360 <span type="species:ncbi:9606">human</span>
Because p53 could exert its repressor activity via interaction with other transcription factors bound to their cognate promoters, we used ChIP assay to test whether p53 is associated with the APE1 promoter in vivo (41). p53(+/+) and p53(-/-) HCT116 cells were treated with CPT for 6 h, and subsequently with 1 mM disuccinimidyl glutarate, which produces protein-protein crosslinks, followed by further incubation with 1% formaldehyde to produce protein-DNA crosslinks. The chromatin fractions were isolated and fragmented by digestion. After immunoprecipitation with antibody to p53 or Sp1, ChIP assays were then performed as described in Materials and Methods section. The amount of immunoprecipitated APE1 promoter sequence was quantitated for each sample by PCR analysis with primers for amplification of the APE1 promoter region from -368 to +24 bp. Figure 6B shows significant enrichment of this sequence in the immunocomplex with p53 antibody, indicating that p53 is associated with the APE1 promoter in vivo in HCT116 p53(+/+) cells. We performed appropriate control experiments to validate our results. Thus, no significant enrichment of the APE1 promoter sequence was observed by the PCR assay in the p53 immunoprecipitate from chromatin fraction of p53(-/-) cells (Figure 6B). Similarly, no significant enrichment of the APE1 promoter sequence was observed in chromatin extracts from either cell line when non-specific IgG was used for immunoprecipitation (Figure 6B). An earlier study identified overlapping Sp1-binding sites within this APE1 promoter sequence (53). As expected, significant enrichment of the APE1 promoter sequence was observed in the Sp1-specific immunocomplexes from both cell lines (Figure 6B), indicating that Sp1 is constitutively associated with the APE1 promoter in the chromatin fraction of both p53(+/+) and p53(-/-) cells. To establish that p53 selectively binds to this (-184 to -143 bp) sequence, we used appropriate primer sequences to amplify the region corresponding to -253 to -118 bp of the APE1 promoter. Figure 6C shows that this sequence was selectively enriched in the p53 immunocomplex from the p53(+/+) but not p53(-/-) HCT116 cells. This confirms binding of p53 to this sequence in vivo. These results provide strong evidence that both p53 and Sp1 are associated with the -253 to -118 bp region in the human APE1 promoter in vivo.
###end p 39
###begin p 40
###xml 49 52 49 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cis</italic>
###xml 259 264 259 264 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trans</italic>
###xml 534 536 534 536 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B41">41</xref>
###xml 682 684 682 684 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B54">54</xref>
###xml 685 687 685 687 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B55">55</xref>
###xml 899 904 899 904 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(&#8722;/&#8722;)</sup>
###xml 1006 1014 1006 1014 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F7">Figure 7</xref>
###xml 1199 1208 1199 1208 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 7.</label>
###xml 1277 1278 1277 1278 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 1283 1288 1283 1288 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(&#8722;/&#8722;)</sup>
###xml 1757 1758 1754 1755 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 2034 2035 2031 2032 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 2070 2075 2067 2072 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(&#8722;/&#8722;)</sup>
###xml 2146 2148 2143 2145 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">32</sup>
###xml 2228 2229 2225 2226 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
###xml 1208 2237 1208 2234 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="41">Effect of TSA on p53-mediated repression of APE1 promoter activity. (<bold>A</bold>) p53<sup>(&#8722;/&#8722;)</sup> cells were transiently transfected with 0.5 &#956;g of APE1 promoter&#8211;luciferase plasmid (&#8722;1800/+65) and increasing amounts of expression plasmid encoding WTp53 or equivalent amounts of empty vector. Twenty-four hours after transfection cells were treated with or without TSA (100 ng/ml) and luciferase activity was measured 48 h after transfection and normalized for the amount of protein. The mean &#177; SD of five independent experiments performed in duplicate is shown. (<bold>B</bold>) Sequence of the DNA probes for EMSA assay with APE1 promoter. Schematic diagram of the APE1 promoter showing some of the putative transcription factor binding sites (Sp1; USF; glucocorticoid response element (GRE); activator protein 1 (AP-1); and CCAAT box-like sequence). (<bold>C</bold>) EMSA with nuclear extracts of p53<sup>(&#8722;/&#8722;)</sup> cells transfected with empty vector or WTp53 expression plasmid using <sup>32</sup>P-labeled duplex oligo corresponding to bases &#8722;177 to &#8722;143 from APE1 promoter; *<italic>P</italic> &lt; 0.05.</p>
###xml 1208 2237 1208 2234 <caption xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="41">Effect of TSA on p53-mediated repression of APE1 promoter activity. (<bold>A</bold>) p53<sup>(&#8722;/&#8722;)</sup> cells were transiently transfected with 0.5 &#956;g of APE1 promoter&#8211;luciferase plasmid (&#8722;1800/+65) and increasing amounts of expression plasmid encoding WTp53 or equivalent amounts of empty vector. Twenty-four hours after transfection cells were treated with or without TSA (100 ng/ml) and luciferase activity was measured 48 h after transfection and normalized for the amount of protein. The mean &#177; SD of five independent experiments performed in duplicate is shown. (<bold>B</bold>) Sequence of the DNA probes for EMSA assay with APE1 promoter. Schematic diagram of the APE1 promoter showing some of the putative transcription factor binding sites (Sp1; USF; glucocorticoid response element (GRE); activator protein 1 (AP-1); and CCAAT box-like sequence). (<bold>C</bold>) EMSA with nuclear extracts of p53<sup>(&#8722;/&#8722;)</sup> cells transfected with empty vector or WTp53 expression plasmid using <sup>32</sup>P-labeled duplex oligo corresponding to bases &#8722;177 to &#8722;143 from APE1 promoter; *<italic>P</italic> &lt; 0.05.</p></caption>
###xml 2237 2237 2234 2234 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="gkm1173f7"/>
###xml 1199 2237 1199 2234 <fig xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="F7" position="float"><label>Figure 7.</label><caption><p textid="41">Effect of TSA on p53-mediated repression of APE1 promoter activity. (<bold>A</bold>) p53<sup>(&#8722;/&#8722;)</sup> cells were transiently transfected with 0.5 &#956;g of APE1 promoter&#8211;luciferase plasmid (&#8722;1800/+65) and increasing amounts of expression plasmid encoding WTp53 or equivalent amounts of empty vector. Twenty-four hours after transfection cells were treated with or without TSA (100 ng/ml) and luciferase activity was measured 48 h after transfection and normalized for the amount of protein. The mean &#177; SD of five independent experiments performed in duplicate is shown. (<bold>B</bold>) Sequence of the DNA probes for EMSA assay with APE1 promoter. Schematic diagram of the APE1 promoter showing some of the putative transcription factor binding sites (Sp1; USF; glucocorticoid response element (GRE); activator protein 1 (AP-1); and CCAAT box-like sequence). (<bold>C</bold>) EMSA with nuclear extracts of p53<sup>(&#8722;/&#8722;)</sup> cells transfected with empty vector or WTp53 expression plasmid using <sup>32</sup>P-labeled duplex oligo corresponding to bases &#8722;177 to &#8722;143 from APE1 promoter; *<italic>P</italic> &lt; 0.05.</p></caption><graphic xlink:href="gkm1173f7"/></fig>
Although there is no evidence for a p53-specific cis element in the APE1 promoter, the presence of p53 in the APE1 promoter complex as indicated by our ChIP assay strongly supports the idea that p53 is recruited to the APE1 promoter via binding to some other trans-acting factors. p53 has been shown to interact with several factors of the basal transcription machinery, e.g. TATA-binding Protein (TBP) or the basal transcription factor Sp1, and also to recruit mSin3A/HDAC repressor complex to the promoter to inhibit transcription (41). Consistent with this, p53-mediated repression of several promoters has been shown to be reversed with the HDAC inhibitor, tricostatin A (TSA) (54,55). To test possible involvement of HDAC in p53-mediated APE1 repression, we used the -1800/+65 APE1-Luc promoter-reporter plasmid which showed the highest promoter activity. At 24 h after cotransfection of HCT116(-/-) cells with the APE1 promoter-reporter and WTp53 plasmids, the cells were treated with 100 ng/ml TSA. Figure 7A shows that TSA reversed p53-mediated repression of luciferase to a significant extent, suggesting that the repression involves p53-dependent recruitment of HDAC to the APE1 promoter. Figure 7.Effect of TSA on p53-mediated repression of APE1 promoter activity. (A) p53(-/-) cells were transiently transfected with 0.5 mug of APE1 promoter-luciferase plasmid (-1800/+65) and increasing amounts of expression plasmid encoding WTp53 or equivalent amounts of empty vector. Twenty-four hours after transfection cells were treated with or without TSA (100 ng/ml) and luciferase activity was measured 48 h after transfection and normalized for the amount of protein. The mean +/- SD of five independent experiments performed in duplicate is shown. (B) Sequence of the DNA probes for EMSA assay with APE1 promoter. Schematic diagram of the APE1 promoter showing some of the putative transcription factor binding sites (Sp1; USF; glucocorticoid response element (GRE); activator protein 1 (AP-1); and CCAAT box-like sequence). (C) EMSA with nuclear extracts of p53(-/-) cells transfected with empty vector or WTp53 expression plasmid using 32P-labeled duplex oligo corresponding to bases -177 to -143 from APE1 promoter; *P < 0.05.
###end p 40
###begin p 41
###xml 69 70 69 70 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 75 80 75 80 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(&#8722;/&#8722;)</sup>
###xml 549 550 546 547 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 826 827 823 824 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 862 867 859 864 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(&#8722;/&#8722;)</sup>
###xml 938 940 935 937 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">32</sup>
###xml 1020 1021 1017 1018 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">P</italic>
Effect of TSA on p53-mediated repression of APE1 promoter activity. (A) p53(-/-) cells were transiently transfected with 0.5 mug of APE1 promoter-luciferase plasmid (-1800/+65) and increasing amounts of expression plasmid encoding WTp53 or equivalent amounts of empty vector. Twenty-four hours after transfection cells were treated with or without TSA (100 ng/ml) and luciferase activity was measured 48 h after transfection and normalized for the amount of protein. The mean +/- SD of five independent experiments performed in duplicate is shown. (B) Sequence of the DNA probes for EMSA assay with APE1 promoter. Schematic diagram of the APE1 promoter showing some of the putative transcription factor binding sites (Sp1; USF; glucocorticoid response element (GRE); activator protein 1 (AP-1); and CCAAT box-like sequence). (C) EMSA with nuclear extracts of p53(-/-) cells transfected with empty vector or WTp53 expression plasmid using 32P-labeled duplex oligo corresponding to bases -177 to -143 from APE1 promoter; *P < 0.05.
###end p 41
###begin title 42
P53-induced APE1 repression is mediated by interference with Sp1 binding to the APE1 promoter
###end title 42
###begin p 43
###xml 190 198 190 198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F7">Figure 7</xref>
###xml 294 302 294 302 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F6">Figure 6</xref>
###xml 376 379 376 379 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cis</italic>
###xml 420 425 420 425 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B56 B57 B58">56&#8211;58</xref>
###xml 593 601 593 601 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F7">Figure 7</xref>
###xml 876 881 876 881 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(&#8722;/&#8722;)</sup>
Identification of one Sp1 site within the putative p53 response element in the APE1 promoter raised the possibility that p53 is recruited by Sp1 to the APE1 promoter complex for inhibition (Figure 7B). ChIP analysis clearly demonstrated association of Sp1 and p53 in the APE1 promoter complex (Figure 6B). p53 has been shown to bind Sp1 and interferes with its binding to the cis element for Sp1-mediated transcription (56-58). To test this possibility, we performed EMSA with APE1's Sp1-binding sequence. Formation of specific protein-DNA complexes suggested the binding of Sp1 to the oligo (Figure 7C), which was competed with unlabeled oligo containing WT but not a mutated Sp1 oligo sequence. These data confirm the specificity of Sp1 binding to this sequence. Furthermore, a significant decrease in binding was observed with nuclear extract from p53-overexpressing HCT116(-/-) cells, suggesting that WTp53 interferes with Sp1 binding to the promoter.
###end p 43
###begin title 44
DISCUSSION
###end title 44
###begin p 45
###xml 209 211 209 211 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
###xml 212 214 212 214 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
###xml 215 217 215 217 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B29">29</xref>
###xml 569 571 566 568 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B59">59</xref>
###xml 766 771 763 768 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(+/+)</sup>
###xml 807 812 804 809 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(&#8722;/&#8722;)</sup>
###xml 845 850 842 847 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(+/+)</sup>
###xml 1724 1727 1721 1724 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cis</italic>
###xml 2072 2077 2069 2074 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trans</italic>
###xml 2095 2097 2092 2094 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B52">52</xref>
APE1 is often overexpressed in tumor cells compared to its basal level in many untransformed cells lines. Downregulation of APE1 was found to sensitize tumor cells to chemotherapy with induction of apoptosis (26,27,29). Thus, elucidating the molecular basis for variable APE1 expression is important from both basic and clinical perspectives. Although several studies have shown that p53 participates in DNA repair processes, and stimulates BER via its direct interaction with APE1 and DNA polymerase beta, whether p53 regulates APE1 level itself was not shown before (59). This report provides the first evidence that p53 downregulates APE1 expression. We have shown that the levels of both APE1 mRNA and polypeptide were decreased after CPT treatment in HCT116 p53(+/+), but not in the isogenic HCT116 p53(-/-) cells. This effect on HCT116 p53(+/+) cells was specific, and not a consequence of general effects of genotoxic or other types of stress, because the same treatment did not affect APE1 expression in p53 null cells. This thus indicates direct relationship between the p53 status and APE1 downregulation. Reduced expression of both endogenous APE1 and APE1 promoter-dependent luciferase activity by exogenous p53 in unstressed p53 null cells further confirmed that p53 downregulates APE1 expression. However, ectopic expression of WTp53 downregulated the episomal APE1 promoter to a much greater extent than the endogenous gene which was somewhat unexpected. It is possible that the APE1 promoter in the chromatinized plasmid is more sensitive to the effect of p53 than the folded conformation in cellular chromatin. Furthermore, the endogenous APE1 gene could be regulated by binding of transcription factors to cis elements absent in the episomal promoter. The V143A p53 mutant lacking DNA-binding activity did not downregulate the basal APE1 promoter as much as did WTp53, which strongly suggests that p53's DNA-binding ability is a prerequisite for its repressor activity. However, the L22G, T23S double mutant with normal DNA-binding activity, but lacking trans-acting activity (52), was also unable to repress the APE1 promoter, which suggests that both DNA binding and transactivation abilities of p53 are required for the repression. Western analysis showing that p53 mutants were more stable than the WTp53 protein eliminated the possibility that the former's inability to repress the APE1 promoter was due to reduced stability.
###end p 45
###begin p 46
###xml 196 199 196 199 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cis</italic>
###xml 571 578 571 578 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 664 667 664 667 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cis</italic>
###xml 854 857 854 857 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cis</italic>
###xml 950 952 950 952 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B41">41</xref>
###xml 953 955 953 955 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B58">58</xref>
###xml 956 958 956 958 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B60">60</xref>
###xml 959 961 959 961 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B61">61</xref>
###xml 1232 1234 1232 1234 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B41">41</xref>
Using functional analysis of nested deletion mutants, we mapped the basal APE1 promoter to a -143 bp segment 5' to the transcription start site. We also observed that the candidate p53-responsive cis element(s) were located in the -184 to -143 bp segment. However, sequence analysis revealed no apparent p53-binding sites within this segment. Moreover, the recombinant p53 polypeptide failed to bind to an oligo of this sequence (-184 to -143). At the same time we have provided direct evidence from ChIP assays that p53 was bound to the -253 to -118 bp segment sequence in vivo. Together, these data suggest that APE1 repression by p53 is not mediated via direct cis element binding, but rather involves p53's indirect recruitment to the promoter by other transcription factors. p53 has been shown to repress many other promoters that lack p53-specific cis elements, indicating that the mechanisms of p53-mediated repression are varied and complex (41,58,60,61). Such mechanisms could include (i) interference with transcriptional activators, (ii) interference with the basal transcription machinery and (iii) compaction of the chromatin structure at the promoter sites by recruitment of HDACs and other histone-modifying enzymes (41).
###end p 46
###begin p 47
###xml 227 235 227 235 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 371 373 371 373 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B53">53</xref>
###xml 475 480 475 480 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(+/+)</sup>
###xml 488 493 488 493 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(&#8722;/&#8722;)</sup>
###xml 544 551 544 551 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 936 941 936 941 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B56 B57 B58">56&#8211;58</xref>
###xml 1163 1165 1163 1165 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B57">57</xref>
###xml 1166 1168 1166 1168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B58">58</xref>
###xml 1169 1174 1169 1174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B60 B61 B62 B63">60&#8211;63</xref>
The exact mechanism by which p53 represses the APE1 expression is not clear. We have shown that candidate p53-responsive element(s) were located in the -184 to -143 bp segment that includes one Sp1 site. An earlier study using in vitro DNase I footprinting analysis with purified Sp1 polypeptide showed a distinct footprint spanning -169 to -148 bp in the APE1 promoter (53). Consistent with this, our ChIP assay showed constitutive Sp1 binding within this region in both p53(+/+) and p53(-/-) cells, indicating that the Sp1 site is functional in vivo. Moreover, we observed that Sp1 remains bound to the APE1 promoter after p53 activation by CPT, suggesting that both p53 and Sp1 can simultaneously occupy the same promoter region. It thus appears that repression may be achieved through the physical interaction of p53 with Sp1. Consistent with this possibility, p53 has been shown to bind Sp1, inhibiting Sp1-mediated transcription (56-58). However, in P53-dependent repression of the telomerase reverse transcriptase, insulin receptor, VEGF and POLD1 genes, p53 does not inhibit DNA binding by Sp1, but rather interferes with its ability for transactivation (57,58,60-63). We also observed that overexpression of p53 decreased DNA binding by Sp1. On the other hand, treatment with HDAC inhibitor TSA partially abolished p53-mediated repression of the APE1 promoter indicating HDAC recruitment to the promoter site. Thus the mechanism of p53-mediated repression of the APE1 gene appears to be multifaceted.
###end p 47
###begin p 48
###xml 229 231 229 231 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B28">28</xref>
###xml 232 234 232 234 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B29">29</xref>
###xml 708 710 708 710 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B64">64</xref>
###xml 711 713 711 713 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B65">65</xref>
###xml 702 706 <span type="species:ncbi:10116">rats</span>
Our findings are intriguing because p53 acts as a pro-apoptotic factor in the cellular response to stress, whereas APE1 is a pro-survival protein whose DNA repair function is essential for protecting cells from oxidative damage (28,29). However, it is possible that the tumor suppressor function of p53 is mediated in part by transcriptional repression of antiapoptotic genes such as APE1. Thus the cell could use p53 to downregulate APE1 expression in response to severe DNA damage, thereby promoting apoptosis. Consistent with this idea, several earlier studies showed reduction of APE1 expression during apoptosis in myeloid leukemia cells and in neurons after transient global cerebral ischemia in rats (64,65). Additional studies are needed to unravel the physiological significance of such downregulation.
###end p 48
###begin p 49
###xml 423 425 423 425 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 426 428 426 428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B47">47</xref>
Our study also sheds light on the potential link between APE1 expression and p53 status in different tumors with their resistance to chemotherapeutic drugs. Although only few published studies have directly focused on the potential link between APE1 expression and p53 status in various tumors, an inverse relationship between APE1 nuclear expression and p53 nuclear accumulation has been reported in head and neck cancer (24,47). It is interesting to speculate that tumors with mutated p53 also have high APE1 levels and develop resistance to therapy, while induction of WTp53 in other tumors will reduce their APE1 levels, leading to enhanced therapeutic index of efficacy of the anticancer drugs. Thus the p53-mediated suppression of APE1 expression could offer a potential approach for sensitizing tumor cells to drugs.
###end p 49
###begin title 50
ACKNOWLEDGEMENTS
###end title 50
###begin p 51
We acknowledge the help of Dr D. Bocangel for this study and we thank Dr D. Konkel for critically editing the manuscript. This work was funded by National Institute of Health (R01 ES08457, R01 CA53791 to S.M. and CA98664 to T.I.), American Heart Association grant (AHA#0565008Y to K.B.). Amira Zaky was supported by a Government of Egypt scholarship for research at University of Texas medical Branch. Funding to pay the Open Access publication charges were waived by Oxford University Press.
###end p 51
###begin p 52
###xml 0 30 0 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Conflict of interest statement</italic>
Conflict of interest statement. None declared.
###end p 52
###begin title 53
REFERENCES
###end title 53
###begin article-title 54
Repair of oxidative damage to DNA: enzymology and biology
###end article-title 54
###begin article-title 55
Choreography of oxidative damage repair in mammalian genomes
###end article-title 55
###begin article-title 56
Intracellular trafficking and regulation of mammalian AP-endonuclease 1 (APE1), an essential DNA repair protein
###end article-title 56
###begin article-title 57
Hypersensitivity phenotypes associated with genetic and synthetic inhibitor-induced base excision repair deficiency
###end article-title 57
###begin article-title 58
Identification and characterization of Ref-1, a nuclear protein that facilitates AP-1 DNA-binding activity
###end article-title 58
###begin article-title 59
Identification of redox/repair protein Ref-1 as a potent activator of p53
###end article-title 59
###begin article-title 60
Going APE over ref-1
###end article-title 60
###begin article-title 61
###xml 6 9 <span type="species:ncbi:4456">Ape</span>
###xml 124 127 <span type="species:ncbi:10116">rat</span>
Ref-1/Ape is critical for formation of the hypoxia-inducible transcriptional complex on the hypoxic response element of the rat pulmonary artery endothelial cell VEGF gene
###end article-title 61
###begin article-title 62
A redox factor protein, ref1, is involved in negative gene regulation by extracellular calcium
###end article-title 62
###begin article-title 63
###xml 19 24 <span type="species:ncbi:9606">human</span>
Role of acetylated human AP-endonuclease (APE1/Ref-1) in regulation of the parathyroid hormone gene
###end article-title 63
###begin article-title 64
Implication of Ref-1 in the repression of renin gene transcription by intracellular calcium
###end article-title 64
###begin article-title 65
###xml 52 57 <span type="species:ncbi:9606">human</span>
Activation of apurinic/apyrimidinic endonuclease in human cells by reactive oxygen species and its correlation with their adaptive response to genotoxicity of free radicals
###end article-title 65
###begin article-title 66
Apurinic endonuclease (Ref-1) is induced in mammalian cells by oxidative stress and involved in clastogenic adaptation
###end article-title 66
###begin article-title 67
TSH controls Ref-1 nuclear translocation in thyroid cells
###end article-title 67
###begin article-title 68
###xml 33 38 <span type="species:ncbi:9606">human</span>
Negative regulation of the major human AP-endonuclease, a multifunctional protein
###end article-title 68
###begin article-title 69
Key role of a downstream specificity protein 1 site in cell cycle-regulated transcription of the AP endonuclease gene APE1/APEX in NIH3T3 cells
###end article-title 69
###begin article-title 70
Elevated and altered expression of the multifunctional DNA base excision repair and redox enzyme Ape1/ref-1 in prostate cancer
###end article-title 70
###begin article-title 71
Prognostic significance of Ape1/ref-1 subcellular localization in non-small cell lung carcinomas
###end article-title 71
###begin article-title 72
Altered expression of Ape1/ref-1 in germ cell tumors and overexpression in NT2 cells confers resistance to bleomycin and radiation
###end article-title 72
###begin article-title 73
The apurinic/apyrimidinic endonuclease (APE/ref-1) DNA repair enzyme is elevated in premalignant and malignant cervical cancer
###end article-title 73
###begin article-title 74
The intracellular localization of APE1/Ref-1: more than a passive phenomenon?
###end article-title 74
###begin article-title 75
Alterations in the expression of the DNA repair/redox enzyme APE/ref-1 in epithelial ovarian cancers
###end article-title 75
###begin article-title 76
###xml 43 48 <span type="species:ncbi:9606">human</span>
###xml 113 118 <span type="species:ncbi:9606">human</span>
Expression and subcellular localization of human AP endonuclease 1 (HAP1/Ref-1) protein: a basis for its role in human disease
###end article-title 76
###begin article-title 77
###xml 22 27 <span type="species:ncbi:9606">human</span>
Nuclear expression of human apurinic/apyrimidinic endonuclease (HAP1/Ref-1) in head-and-neck cancer is associated with resistance to chemoradiotherapy and poor outcome
###end article-title 77
###begin article-title 78
Studies of apurinic/apyrimidinic endonuclease/ref-1 expression in epithelial ovarian cancer: correlations with tumor progression and platinum resistance
###end article-title 78
###begin article-title 79
Down-regulation of apurinic/apyrimidinic endonuclease expression is associated with the induction of apoptosis in differentiating myeloid leukemia cells
###end article-title 79
###begin article-title 80
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human apurinic endonuclease 1 (APE1) expression and prognostic significance in osteosarcoma: enhanced sensitivity of osteosarcoma to DNA damaging agents using silencing RNA APE1 expression inhibition
###end article-title 80
###begin article-title 81
###xml 74 79 <span type="species:ncbi:9606">human</span>
A vital role for Ape1/Ref1 protein in repairing spontaneous DNA damage in human cells
###end article-title 81
###begin article-title 82
Two essential but distinct functions of the mammalian abasic endonuclease
###end article-title 82
###begin article-title 83
The p53 functional circuit
###end article-title 83
###begin article-title 84
###xml 18 28 <span type="species:ncbi:111938">gatekeeper</span>
p53, the cellular gatekeeper for growth and division
###end article-title 84
###begin article-title 85
p53: puzzle and paradigm
###end article-title 85
###begin article-title 86
P53 in cancer: a paradigm for modern management of cancer
###end article-title 86
###begin article-title 87
Tumor-suppressor p53 and the cell cycle
###end article-title 87
###begin article-title 88
WAF1, a potential mediator of p53 tumor suppression
###end article-title 88
###begin article-title 89
14-3-3 sigma is a p53-regulated inhibitor of G2/M progression
###end article-title 89
###begin article-title 90
Cooperative effects of genes controlling the G(2)/M checkpoint
###end article-title 90
###begin article-title 91
###xml 66 71 <span type="species:ncbi:9606">human</span>
Tumor suppressor p53 is a direct transcriptional activator of the human bax gene
###end article-title 91
###begin article-title 92
PUMA induces the rapid apoptosis of colorectal cancer cells
###end article-title 92
###begin article-title 93
PUMA, a novel proapoptotic gene, is induced by p53
###end article-title 93
###begin article-title 94
Transcriptional repression mediated by the p53 tumour suppressor
###end article-title 94
###begin article-title 95
###xml 46 51 <span type="species:ncbi:9606">human</span>
Wild-type p53 suppresses transcription of the human O6-methylguanine-DNA methyltransferase gene
###end article-title 95
###begin article-title 96
p53 is involved in regulation of the DNA repair gene O6-methylguanine-DNA methyltransferase (MGMT) by DNA damaging agents
###end article-title 96
###begin article-title 97
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway
###end article-title 97
###begin article-title 98
The insulin-like growth factor I receptor as a physiologically relevant target of p53 in apoptosis caused by interleukin-3 withdrawal
###end article-title 98
###begin article-title 99
###xml 120 125 <span type="species:ncbi:9606">human</span>
Enforced expression of wild-type p53 curtails the transcription of the O(6)-methylguanine-DNA methyltransferase gene in human tumor cells and enhances their sensitivity to alkylating agents
###end article-title 99
###begin article-title 100
###xml 32 37 <span type="species:ncbi:9606">human</span>
Levels of the DNA repair enzyme human apurinic/apyrimidinic endonuclease (APE1, APEX, Ref-1) are associated with the intrinsic radiosensitivity of cervical cancers
###end article-title 100
###begin article-title 101
###xml 15 20 <span type="species:ncbi:9606">human</span>
Acetylation of human 8-oxoguanine-DNA glycosylase by p300 and its role in 8-oxoguanine repair in vivo
###end article-title 101
###begin article-title 102
###xml 42 46 <span type="species:ncbi:10090">mice</span>
A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy
###end article-title 102
###begin article-title 103
Pifithrin-alpha inhibits p53 signaling after interaction of the tumor suppressor protein with hsp90 and its nuclear translocation
###end article-title 103
###begin article-title 104
Pifithrin-alpha, an inhibitor of p53 transactivation, alters the inflammatory process and delays tendon healing following acute injury
###end article-title 104
###begin article-title 105
Several hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein
###end article-title 105
###begin article-title 106
###xml 47 52 <span type="species:ncbi:9606">human</span>
Characterization of the promoter region of the human apurinic endonuclease gene (APE)
###end article-title 106
###begin article-title 107
Wild-type p53 negatively regulates the expression of a microtubule-associated protein
###end article-title 107
###begin article-title 108
Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A
###end article-title 108
###begin article-title 109
###xml 132 137 <span type="species:ncbi:9606">human</span>
Induction of Sp1-p53 DNA-binding heterocomplexes during granulocyte/macrophage colony-stimulating factor-dependent proliferation in human erythroleukemia cell line TF-1
###end article-title 109
###begin article-title 110
p53-mediated repression of alpha-fetoprotein gene expression by specific DNA binding
###end article-title 110
###begin article-title 111
Repression of the insulin receptor promoter by the tumor suppressor gene product p53: a possible mechanism for receptor overexpression in breast cancer
###end article-title 111
###begin article-title 112
A role for p53 in base excision repair
###end article-title 112
###begin article-title 113
###xml 86 91 <span type="species:ncbi:9606">human</span>
Adenoviral expression of p53 represses telomerase activity through down-regulation of human telomerase reverse transcriptase transcription
###end article-title 113
###begin article-title 114
###xml 41 46 <span type="species:ncbi:9606">human</span>
Wild-type p53 suppresses angiogenesis in human leiomyosarcoma and synovial sarcoma by transcriptional suppression of vascular endothelial growth factor expression
###end article-title 114
###begin article-title 115
###xml 34 39 <span type="species:ncbi:9606">human</span>
Transcriptional regulation of the human DNA polymerase delta catalytic subunit gene POLD1 by p53 tumor suppressor and Sp1
###end article-title 115
###begin article-title 116
Divergent regulation of the growth-promoting gene IEX-1 by the p53 tumor suppressor and Sp1
###end article-title 116
###begin article-title 117
Down-regulation of apurinic/apyrimidinic endonuclease 1/redox factor-1 expression by soy isoflavones enhances prostate cancer radiotherapy in vitro and in vivo
###end article-title 117
###begin article-title 118
Loss of Ref-1 protein expression precedes DNA fragmentation in apoptotic neurons
###end article-title 118

